New Antibiotics Produced by Gene Editing

A novel way of manipulating key assembly line enzymes in bacteria which could pave the way for a new generation of antibiotic treatments has been discovered by researchers.

A novel way of manipulating key assembly line enzymes in bacteria which could pave the way for a new generation of antibiotic treatments has been discovered by The University of Manchester researchers.

New research published today in Nature Communications, describes how CRISPR-cas9 gene editing can be used to create new nonribosomal peptide synthetase (NRPS) enzymes that deliver clinically important antibiotics. NRPS enzymes are prolific producers of natural antibiotics such as penicillin. However, up until know, manipulating these complex enzymes to produce new and more effective antibiotics has been a major challenge.

Antibiotics - Use and Abuse
Antibiotics are among the most used and abused medications. This article explains some general features about antibiotics.

‘Scientists have discovered a new route to produce complex antibiotics exploiting gene editing to re-programme pathways to future medicines urgently required to combat antimicrobial resistance, treat neglected diseases and prevent future pandemics.’

The problem of antimicrobial resistance

The UK government suggest, antimicrobial resistance (AMR) infections are estimated to cause 700,000 deaths each year globally and are predicted to rise to 10 million, costing the global economy $100 trillion, by 2050. AMR also threatens many of the UN’s Sustainable Development Goals (SDGs), with an extra 28 million people that could be forced into extreme poverty by 2050 unless AMR is contained.

The Manchester team says the gene editing process could be used to produce improved antibiotics and possibly lead to the development of new treatments helping in the fight against drug-resistant pathogens and illnesses in the future. Jason Micklefield, Professor of Chemical Biology at the Manchester Institute of Biotechnology, UK, explains: “The emergence of antibiotic-resistant pathogens is one of the biggest threats we face today.”

Interaction of Antibiotics with Dairy Products
Antibiotics like tetracyclines and fluoroquinolones used in the treatment of bacterial infections interact mainly with dairy products and lead to adverse side effects.

“The gene editing approach we developed is a very efficient and rapid way to engineer complex assembly line enzymes that can produce new antibiotic structures with potentially improved properties.”

The potential of nonribosomal peptide antibiotics

Natural Antibiotics to Fight Bacterial Infections
Fighting infections the natural way and preventing them is always more effective than consuming medicines and antibiotics to treat them.

Microorganisms in our environment, such as soil dwelling bacteria, have evolved nonribosomal peptide synthetase enzymes (NRPS) that assemble building blocks called amino acids into peptide products which often have very potent antibiotic activity. Many of the most therapeutically important antibiotics, used in the clinic today, are derived from these NRPS enzymes (e.g. penicillin, vancomycin and daptomycin).

Unfortunately, deadly pathogens are emerging which are resistant to all of these existing antibiotic drugs. One solution could be to create new antibiotics with improved properties that can evade the resistance mechanisms of the pathogens. However, the nonribosomal peptide antibiotics are very complex structures which are difficult and expensive to produce by normal chemical methods. To address this, the Manchester team use gene editing to engineer the NRPS enzymes, swapping domains that recognise different amino acid building, leading to new assembly lines that can deliver new peptide products.

Quiz on Antibiotics
Your doctor may suggest antibiotics at the first sight of an infection, but how much do you really know about these wonder drugs? Test yourself.

Micklefield added: “We are now able to use gene editing to introduce targeted changes to complex NRPS enzymes, introducing alternative amino acids precursors into peptide structures. We are optimistic that our new approach could lead to new ways of making improved antibiotics which are urgently needed to combat emerging drug-resistant pathogens.”

Source-Eurekalert